Echinocandin use in the neonatal intensive care unit;Uso de Equinocandinas en la Unidad de Cuidados Intensivos Neonatal

Annals of Pharmacotherapy

Volumn 46, Issue 1, 2012, Pages 108-116

  Caudle, Kelly E ^a   Inger, Amanda G ^b   Butler, Dawn R ^a   David Rogers, P ^c  

^a UNIVERSITY OF CINCINNATI   (United States)

^b Department of Electrical Engineering and Computer Science   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Caspofungin; Echinocandin; Infant; Micafungin; Neonate; NICU

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; MICAFUNGIN;

AREA UNDER THE CURVE; CANDIDA; CANDIDIASIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TISSUE LEVEL; HUMAN; HYPERCALCEMIA; HYPOKALEMIA; MAXIMUM PLASMA CONCENTRATION; NEWBORN INTENSIVE CARE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

ANTIFUNGAL AGENTS; CANDIDIASIS, INVASIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; ECHINOCANDINS; HUMANS; INFANT, NEWBORN; INTENSIVE CARE UNITS, NEONATAL; INTENSIVE CARE, NEONATAL; LIPOPEPTIDES; TREATMENT OUTCOME;

EID: 84855649786     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q346     Document Type: Review

References (39)

1. Stoll BJ, Hansen N, Fanaroff AA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics 2002;110:285-91.
2. Saiman L, Ludington E, Pfaller M, et al. Risk factors for candidemia in neonatal intensive care unit patients. The National Epidemiology of Mycosis Survey study group. Pediatr Infect Dis J 2000;19:319-24.
3. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007;20:133-63. DOI 20/1/133 [pii]10.1128/CMR.00029-06
4. Zaoutis TE, Greves HM, Lautenbach E, Bilker WB, Coffin SE. Risk factors for disseminated candidiasis in children with candidemia. Pediatr Infect Dis J 2004;23:635-41. DOI 00006454-200407000-00009 [pii]
5. Garey KW, Rege M, Pai MP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006;43:25-31. DOI 10.1086/504810
6. Benjamin DK Jr, Poole C, Steinbach WJ, Rowen JL, Walsh TJ. Neonatal candidemia and end-organ damage: a critical appraisal of the literature using meta-analytic techniques. Pediatrics 2003;112:634-40.
7. Friedman S, Richardson SE, Jacobs SE, O'Brien K. Systemic Candida infection in extremely low birth weight infants: short term morbidity and long term neurodevelopmental outcome. Pediatr Infect Dis J 2000;19:499-504.
8. Pfaller MA, Diekema DJ, Jones RN, Messer SA, Hollis RJ. Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. J Clin Microbiol 2002;40:852-6.
9. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009;48:503-35. DOI 10.1086/596757
10. Steinbach WJ, Perfect JR. Neonatal and pediatric pharmacology: therapeutic principles and practice. 4th ed. Philadelphia: Lippincot Williams &Wilkins, 2011.
11. Pfaller MA, Boyken L, Hollis RJ, et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 2008;46:150-6. DOI 10.1128/JCM.01901-07
12. Kossoff EH, Buescher ES, Karlowicz MG. Candidemia in a neonatal intensive care unit: trends during fifteen years and clinical features of 111 cases. Pediatr Infect Dis J 1998;17:504-8.
13. Rangel-Frausto MS, Wiblin T, Blumberg HM, et al. National epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infect Dis 1999;29:253-8. DOI 10.1086/520194
14. VandenBussche HL, Van Loo DA. A clinical review of echinocandins in pediatric patients. Ann Pharmacother 2010;44:166-77. DOI 10.1345/aph.1M139
15. Chen SC, Slavin MA, Sorrell TC. Echinocandin antifungal drugs in fungal infections: a comparison. Drugs 2011;71:11-41. DOI 10.2165/11585270-000000000-00000
16. Walsh TJ, Adamson PC, Seibel NL, et al. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother 2005;49:4536-45. DOI 10.1128/AAC.49.11.4536-4545.2005
17. Seibel NL, Schwartz C, Arrieta A, et al. Safety, tolerability, and pharmacokinetics of micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother 2005;49:3317-24. DOI 10.1128/AAC.49.8.3317-3324.2005
18. Stone JA, Xu X, Winchell GA, et al. Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma. Antimicrob Agents Chemother 2004;48:815-23.
19. Sáez-Llorens X, Macias M, Maiya P, et al. Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age. Antimicrob Agents Chemother 2009;53:869-75. DOI 10.1128/AAC.00868-08
20. Heresi GP, Gerstmann DR, Reed MD, et al. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis J 2006;25:1110-5. DOI 10.1097/01.inf.0000245103.07614.e1
21. Smith PB, Walsh TJ, Hope W, et al. Pharmacokinetics of an elevated dosage of micafungin in premature neonates. Pediatr Infect Dis J 2009;28:412-5. DOI 10.1097/INF.0b013e3181910e2d
22. Benjamin DK Jr, Smith PB, Arrieta A, et al. Safety and pharmacokinetics of repeat-dose micafungin in young infants. Clin Pharmacol Ther 2010;87:93-9. DOI 10.1038/clpt.2009.200
23. Hope WW, Mickiene D, Petraitis V, et al. The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. J Infect Dis 2008;197:163-71. DOI 10.1086/524063
24. Cohen-Wolkowiez M, Benjamin DK Jr, Piper L, et al. Safety and pharmacokinetics of multiple-dose anidulafungin in infants and neonates. Clin Pharmacol Ther 2011;89:702-7. DOI 10.1038/clpt.2011.26
25. Queiroz-Telles F, Berezin E, Leverger G, et al. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Pediatr Infect Dis J 2008;27:820-6. DOI 10.1097/INF.0b013e31817275e6
26. Varisco BM, Benner KW, Prabhakaran P. Neonatal peritoneal candidiasis successfully treated with anidulafungin add-on therapy. Ann Pharmacother 2009;43:1907-10. DOI 10.1345/aph.1M350
27. Odio CM, Araya R, Pinto LE, et al. Caspofungin therapy of neonates with invasive candidiasis. Pediatr Infect Dis J 2004;23:1093-7.
28. Belet N, Ciftci E, Ince E, et al. Caspofungin treatment in two infants with persistent fungaemia due to Candida lipolytica. Scand J Infect Dis 2006;38:559-62. DOI 10.1080/00365540500404052
29. Haase R, Kreft B, Foell J, Kekule AS, Merkel N. Successful treatment of Candida albicans septicemia in a preterm infant with severe congenital ichthyosis (Harlequin baby). Pediatr Dermatol 2009;26:575-8. DOI 10.1111/j.1525-1470.2009.00989.x
30. Natarajan G, Lulic-Botica M, Rongkavilit C, Pappas A, Bedard M. Experience with caspofungin in the treatment of persistent fungemia in neonates. J Perinatol 2005;25:770-7. DOI 10.1038/sj.jp.7211380
31. Natale F, Castronovo A, Regoli D, De Curtis M, Manzoni P. Successful treatment with caspofungin of refractory Candida krusei candidemia in a very low birth weight preterm infant. Pediatr Infect Dis J 2009;28:452. DOI 10.1097/INF.0b013e31819d1cf1
32. Filippi L, Poggi C, Gozzini E, Meleleo R, Mirabile L, Fiorini P. Neonatal liver abscesses due to Candida infection effectively treated with caspofungin. Acta Paediatr 2009;98:906-9. DOI 10.1111/j.1651-2227.2009.01225.x
33. Castagnola E, Franceschi A, Natalizia AR, Mantero E, Tuo P. Combined antifungal therapy for persistent central venous catheter-related candidemia in extremely low birth weight neonates. J Chemother 2009;21:234-5.
34. Yalaz M, Akisu M, Hilmioglu S, Calkavur S, Cakmak B, Kultursay N. Successful caspofungin treatment of multidrug resistant Candida parapsilosis septicaemia in an extremely low birth weight neonate. Mycoses 2006;49:242-5. DOI 10.1111/j.1439-0507.2006.01220.x
35. Manzar S, Kamat M, Pyati S. Caspofungin for refractory candidemia in neonates. Pediatr Infect Dis J 2006;25:282-3. DOI 10.1097/01.inf.0000200141.46957.7100006454-200603000-00034 [pii]
36. Kawaguchi C, Arai I, Yasuhara H, Sano R, Nishikubo T, Takahashi Y. Efficacy of micafungin in treating four premature infants with candidiasis. Pediatr Int 2009;51:220-4. DOI 10.1111/j.1442-200X.2008.02726.x
37. Natarajan G, Lulic-Botica M, Aranda JV. Refractory neonatal candidemia and high-dose micafungin pharmacotherapy. J Perinatol 2009;29:738-43. DOI 10.1038/jp.2009.75
38. Kawada M, Fukuoka N, Kondo M, et al. Pharmacokinetics of prophylactic micafungin in very-low-birth-weight infants. Pediatr Infect Dis J 2009;28:840-2. DOI 10.1097/INF.0b013e3181a0cfd1
39. Young TE, Mangum B. Neofax 2009. 22 ed. Ann Arbor, MI: Thomson Reuters, 2009.